“I think it’s a wonderful thing that we did today.” — FDA advisor Michael Sprintz, DO, of the Sprintz Center for Pain in Texas, after recommending the agency approve an over-the-counter naloxone (Narcan) product for reversing opioid overdoses.
“It’s oftentimes hit or miss, and you have to be very nimble.” — Phil Ayers, PharmD, president-elect of the American Society for Parenteral and Enteral Nutrition, commenting on the decades-long supply shortage for parenteral nutrition.
“Before our research, the only established way to delay myopia onset [was] to increase outdoor time, and … the efficacy is quite modest.” — Jason Yam, MPH, of the Chinese University of Hong Kong and Hong Kong Eye Hospital, discussing his group’s finding that atropine eyedrops can significantly reduce the incidence of myopia in children over a 2-year period.
“You are your kid’s best hope.” — Alana Newhouse, president of the Foundation for Angelman Syndrome Therapeutics, after launching a biotech company to drive drug development for her child’s rare disease.
“There’s not any reason that primary care providers and transplant centers should not be fully considering these patients for these life-saving medical procedures.” — Brittany Hand, PhD, of Ohio State University School of Health and Rehabilitation Sciences in Columbus, after finding adults with intellectual and developmental disabilities were less likely to receive a kidney transplant.
“[W]hen he was CEO of Pharmacyclics … he was literally reading children’s books to better understand human biology.” — Former Forbes senior editor Nathan Vardi talking about Bob Duggan, who is mentioned in his new book For Blood and Money.
“That’s very different from what used to happen, which was hospitals and large groups buying you out, and that’s the end of it.” — An Arizona-based cardiologist, on private equity buyers scoping out private cardiovascular practices.
“This is a major problem for understanding long COVID, but primarily for patient management.” — Tiago Teodoro, MD, PhD, of St. George’s Hospital in London, on the possibility that some people labeled with long COVID may have a functional neurological disorder.
“It should not take advantage of the trust … to promote its own independent interests.” — 74-year-old John Heafield of Asheville, North Carolina, after he received a message to his electronic health record portal about enrolling in a Medicare Advantage plan.
“The magnitude of the increase in risk was pretty striking.” — David Hyman, JD, MD, of Georgetown University Law Center in Washington, D.C., on his study that found physicians who had a prior paid medical malpractice claim were up to four times more likely to be hit with a future claim.
Please enable JavaScript to view the